PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: Placebo

First Posted Date: 2007-10-11

Last Posted Date: 2012-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 551

Registration Number: NCT00542685

Locations: 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Phase 2

Completed

Conditions: Dental Pain

Interventions: Drug: Placebo; oral
Drug: ARRY-371797, p38 inhibitor; oral

First Posted Date: 2007-10-10

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 103

Registration Number: NCT00542035

Locations: 🇺🇸
SCIREX Research Center, Salt Lake City, Utah, United States

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

Phase 2

Completed

Conditions: Weight Management
Treatment Of Obesity

Interventions: Drug: CE-326,597 100 mg QD
Drug: CE-326,597 50 mg QD
Drug: CE-326,597 25 mg QD
Drug: Placebo
Drug: CE-326,597 5mg QD

First Posted Date: 2007-10-10

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT00542009

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

Anidulafungin In Treatment Of Candidemia In Asian Subjects

Phase 3

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2007-10-01

Last Posted Date: 2010-03-09

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00537329

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Phase 1

Completed

Conditions: Generalized Anxiety Disorder

First Posted Date: 2007-10-01

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00537615

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Fesoterodine Flexible Dose Study

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2007-09-27

Last Posted Date: 2009-09-15

Lead Sponsor: Pfizer

Target Recruit Count: 896

Registration Number: NCT00536484

Locations: 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States

ACTiF- Assessment of Closed Tibial Fractures

Phase 2

Completed

Conditions: Tibial Fractures

Interventions: Drug: CP-533, 536
Drug: Placebo
Procedure: Standard of Care
Drug: CP-533,536

First Posted Date: 2007-09-21

Last Posted Date: 2012-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 276

Registration Number: NCT00533377

Locations: 🇹🇷
Pfizer Investigational Site, Izmir, Turkey

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo capsules
Drug: PF-03654746

First Posted Date: 2007-09-19

Last Posted Date: 2016-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00531752

Locations: 🇺🇸
Bay Area Research Institute, Lafayette, California, United States
🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸
New York University School of Medicine, New York, New York, United States

and more 3 locations

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Phase 3

Completed

Conditions: Aspergillosis

Interventions: Drug: voriconazole
Drug: anidulafungin

First Posted Date: 2007-09-18

Last Posted Date: 2012-04-30

Lead Sponsor: Pfizer

Target Recruit Count: 459

Registration Number: NCT00531479

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin

First Posted Date: 2007-09-12

Last Posted Date: 2011-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 96

Registration Number: NCT00528619

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy